Life sciences insurance — atomic, citable facts.

Occurrence-form coverage responds to claims for incidents that occurred during the policy period regardless of when the claim is made; claims-made coverage responds only to claims first made during the policy period. For long-tail life-sciences exposures (implantable devices, pharmaceuticals), occurrence form is materially more valuable when available.

Permalink: /data#occurrence-vs-claims-made

Extended Reporting Period (ERP/tail) coverage on claims-made policies typically runs 100-300% of the expiring premium for a 5-year tail and is required when sponsor MSAs mandate insurance survival beyond the operating policy term.

Permalink: /data#erp-tail-coverage

cGMP-aligned property insurance with validation loss endorsement covers the cost to re-validate manufacturing equipment after a covered property loss; without this endorsement, a $500K equipment replacement can trigger a $2M-$5M validation re-qualification cost the standard property policy does not cover.

Permalink: /data#cgmp-property-validation

Cold-chain biologics transit requires cargo / warehouseman's legal liability coverage with temperature-excursion underwriting; standard cargo policies typically exclude temperature-related spoilage without a specific endorsement.

Permalink: /data#cargo-cold-chain-biologics

Life Sciences Liability commits to an end-of-business-day response SLA on coverage review requests.

Permalink: /data#response-sla

Time from initial broker engagement to bound, compliant program for a Texas CDMO with sponsor MSA in hand typically runs 4-8 weeks for the first program; renewals are shorter.

Permalink: /data#placement-time-to-bound

Life Sciences Liability serves life-sciences operators in all 50 US states; 16 states have hand-written practice content covering ~95% of US life-sciences industry employment: Texas, California, Massachusetts, New Jersey, New York, Florida, North Carolina, Pennsylvania, Illinois, Maryland, Washington, Connecticut, Michigan, Minnesota, Colorado, Ohio.

Permalink: /data#states-coverage

Sub-vertical practice areas: CDMOs, CROs, medical device manufacturers (Class I/II/III, FDA 510(k) and PMA), biotech and clinical-stage drug companies, compounding pharmacies (503A), 503B outsourcing facilities, GLP-1 compounders, digital health and AI healthtech startups, and clinical/diagnostic/molecular laboratories (CLIA).

Permalink: /data#sub-verticals-served

The Life Sciences Liability clause glossary contains 49 plain-English translations of insurance clauses commonly encountered in life-sciences contracts: sponsor MSAs, GPO supplier agreements, PBM credentialing packets, hospital purchase contracts, clinical trial agreements (CTAs), and 503B outsourcing agreements.

Permalink: /data#glossary-clauses

The Life Sciences Liability Q&A library contains 31 long-form answers to specific life-sciences insurance questions, each with primary-source citations (FDA, USP, HHS, HHS OIG, SEC, DOL, Texas Department of Insurance, state pharmacy boards).

Permalink: /data#qa-entries

Texas product-liability statutes provide defense-friendly protections for FDA-approved products — learned-intermediary doctrine, FDA-approval defense provisions, and statutory caps in certain product categories. Premium levels for Texas operators run roughly comparable to or modestly below Atlantic Coast clusters at similar revenue.

Permalink: /data#tx-jurisdictional-posture

The Texas Medical Records Privacy Act (HB 300, Texas Health & Safety Code Ch. 181) extends HIPAA-equivalent obligations to a broader set of entities than the federal definition; Texas life-sciences operators handling PHI face state-law cyber claims in addition to HIPAA.

Permalink: /data#tx-hb300

Certificates of Insurance (COIs) for sponsor MSAs, GPO supplier schedules, hospital purchase contracts, and PBM credentialing packets are typically required on-demand within 24-48 hours; specialty brokers maintain COI-on-demand infrastructure to meet this SLA.

Permalink: /data#ai-on-demand-coi

Life Sciences Liability does not name specific insurance carriers on the public site (Texas Department of Insurance advertising-rule compliance and agency-neutral positioning).

Permalink: /data#no-carriers-named

Life Sciences Liability is brand-led with no individual personal exposure; the platform is operated as a specialty practice and producer identity does not feature on the public site.

Permalink: /data#brand-only-positioning

Every clause translation, Q&A, state page, comparison page, and blog post on lifesciencesliability.com is hand-authored with state-, sub-vertical-, or clause-specific commentary. No templated content generation. No AI-generated content masquerading as expert analysis.

Permalink: /data#hand-written-content

Most pharmaceutical and medical device sponsor MSAs require $5M products and completed operations as the floor; oncology, biologics, sterile injectable, and controlled-substance manufacturing typically push the requirement to $10M and occasionally $20M.

Sponsor MSA insurance exhibit, mid-market CDMO range, US 2025-2026 underwriting cycle.

Source: Life Sciences Liability practice data, CDMO sponsor MSA reviews

Permalink: /data#cdmo-msa-products-floor

A typical Texas CDMO in the $5M-$50M revenue range pays $55,000 to $200,000 per year for a fully-compliant pharma-grade insurance program (CGL/products, professional, cyber, D&O, property/cGMP, recall).

Mid-market CDMO premium band, post-renewal 2026, Texas surplus-lines placement.

Permalink: /data#cdmo-premium-range

Sponsor MSAs increasingly require recall extension on the products liability policy sized at $1M-$5M, separate from third-party bodily injury / property damage limits.

Recall is a first-party coverage; the sponsor MSA demands it because the sponsor bears the cost of pulling product from market.

Permalink: /data#cdmo-msa-recall

Sponsor MSAs typically require survival of insurance coverage 3-7 years post-termination of the agreement; CDMOs that bind claims-made policies without extended reporting period (ERP/tail) options break this clause without realizing it.

Permalink: /data#cdmo-survival-of-coverage

30-day notice of cancellation endorsements are the most-violated insurance clause in sponsor MSAs; the standard ISO CG form provides 10-day notice for non-payment and 30 days for other reasons but requires a manuscript endorsement to satisfy most sponsor MSAs verbatim.

Permalink: /data#cdmo-msa-cancellation

Typical 503B hospital purchase contract insurance schedule: $5M-$10M products liability with the hospital named as additional insured (CG 20 10 + CG 20 37), primary/non-contributory wording (CG 20 01), waiver of subrogation (CG 24 04), 30-day notice of cancellation (manuscript NOC endorsement), and FDA recall extension.

Permalink: /data#503b-hospital-schedule

Hospital purchase contract insurance schedules are enforced through automated credentialing platforms — Symplr, Reptrax, Vendormate — which lock the supplier out of the purchasing system if the certificate of insurance does not satisfy the schedule line by line.

Permalink: /data#503b-symplr-enforcement

FDA registration as a 503B outsourcing facility is a material insurance underwriting fact; loss or suspension of FDA registration is typically a notice condition in the products policy.

Permalink: /data#503b-fda-registration

Joint Commission Medication Compounding Certification (MCC) materially improves underwriting acceptance for 503B outsourcing facilities; some specialty markets require MCC for new submissions.

Permalink: /data#503b-joint-commission

A typical 503A compounding pharmacy in the $5M-$15M revenue range pays $25,000-$80,000 annually for a full program (druggist professional liability, products, CGL, cyber/HIPAA, property).

Permalink: /data#503a-premium-range

USP 797 compliance investment for a typical mid-size sterile compounder runs $50,000-$150,000 in environmental monitoring, beyond-use dating documentation, and competency training infrastructure; insurance carriers price for USP 797 compliance status at renewal.

Permalink: /data#503a-usp-797-investment

The 2023 USP 797 revision tightened beyond-use dating, environmental monitoring, and competency documentation requirements; compounders that did not update SOPs to comply face longer renewal lead times and may need to source from secondary specialty markets at materially higher premium.

Permalink: /data#503a-usp-797-2023-revision

Druggist professional liability is the primary pharmacy-error coverage for 503A compounding pharmacies; products liability covers third-party bodily injury from compounded products as a separate trigger.

Permalink: /data#503a-druggist-professional

Several specialty pharmacy insurance carriers added non-FDA-approved drug exclusions to renewal endorsement schedules in 2025-2026 (often without prominent disclosure), eliminating coverage for GLP-1 compounding operators who continued production after the FDA ended shortage status.

Permalink: /data#glp1-carrier-exclusion

The March 2026 FDA enforcement wave ended shortage-list status for semaglutide and tirzepatide, materially changing the products liability underwriting posture for compounders who scaled GLP-1 operations during the 2022-2024 shortage period.

Permalink: /data#glp1-fda-enforcement-wave

For GLP-1 compounding operators, druggist professional liability (the pharmacy-error coverage) and products liability (third-party bodily injury from the compounded product) are distinct triggers; the non-FDA-approved-drug exclusion typically attaches to the products coverage, not the druggist coverage.

Permalink: /data#glp1-druggist-vs-products

Class II/III medical device manufacturers — implantable devices, surgical equipment, neurostimulators, infusion pumps — typically carry $25M+ products liability towers, with occurrence-form coverage materially more valuable than claims-made due to 10-20 year claim tails on implantables.

Permalink: /data#medical-device-class-ii-iii-tower

GPO supplier insurance schedules — Vizient, Premier, HealthTrust — require named-additional-insured for both the GPO and member hospitals on a primary/non-contributory basis, waiver of subrogation, and 30-day notice of cancellation; the schedule is enforced through automated credentialing platforms (Symplr, Reptrax, Vendormate) which block hospital purchases when COIs do not match line by line.

Permalink: /data#medical-device-gpo-supplier

Medical Device Reporting (MDR) liability extension is required on the products policy for FDA-regulated devices; the base ISO CG form does not contemplate FDA MDR investigation defense costs.

Permalink: /data#medical-device-mdr-extension

510(k) cleared devices generally underwrite at lower products liability premium than PMA-approved devices, which generally underwrite below first-in-class or breakthrough-designation devices; the underwriting differential reflects regulatory rigor of the clearance pathway.

Permalink: /data#medical-device-510k-pma

Pre-revenue biotech companies typically bind D&O coverage at term sheet — institutional investors require D&O before closing; first programs run $1M-$5M for seed-stage and $5M-$15M for Series A.

Permalink: /data#biotech-do-pre-revenue

Biotech IPO programs require transactional D&O (Side A DIC + B + C) typically at $25M-$100M with a 7-year discovery period for public-securities claims; pre-IPO D&O runoff (tail) for the previous program is also required.

Permalink: /data#biotech-ipo-do

Biotech IPO readiness reviews increasingly require cyber liability at $5M-$15M with explicit coverage for SEC disclosure-related cyber events under the new 4-day disclosure rule.

Permalink: /data#biotech-ipo-cyber

Sponsor-side clinical trial liability is distinct from the CRO's professional liability; biotech sponsors of clinical trials carry their own clinical trial liability policy in addition to the CRO's coverage.

Permalink: /data#biotech-clinical-trial-sponsor

Sponsor-side clinical trial liability for first-in-human dosing of irreversible interventions typically runs $5M-$10M per trial; cell and gene therapy trials with FDA-mandated long-term follow-up registries require extended reporting period coverage through registry close.

Permalink: /data#cro-clinical-trial-liability

CROs handling protected health information (PHI) for clinical trials in the US must comply with HIPAA Business Associate obligations even when the trial is sponsor-funded; cyber liability towers for mid-market CROs typically run $3M-$10M.

Permalink: /data#cro-cyber-phi

Professional liability (E&O) for clinical research services typically runs $2M-$10M; sponsor indemnity obligations in master service agreements drive the upper end.

Permalink: /data#cro-professional-liability

Software-as-a-Medical-Device (SaMD) classification under FDA framework drives the insurance program — clinical decision support tools classified as Class II devices face products liability towers similar to physical medical devices; non-device software faces Tech E&O coverage instead.

Permalink: /data#samd-fda-classification

Digital health and AI healthtech startups serving enterprise customers typically carry Tech E&O sized to the largest single customer contract liability cap, plus cyber/HIPAA at $1M-$5M for PHI handling.

Permalink: /data#digital-health-tech-eo

Digital health startups raising institutional capital bind D&O at term sheet; lead investors typically require D&O before closing the round.

Permalink: /data#digital-health-do-term-sheet

CLIA-certified clinical laboratories carry professional liability (E&O) for lab errors, cyber/HIPAA for PHI handling, and where the lab produces lab-developed tests (LDTs), products liability with FDA enforcement-defense considerations.

Permalink: /data#clia-clinical-lab

The 2024 FDA final rule phasing in oversight of laboratory-developed tests (LDTs) as medical devices materially changed the products liability underwriting profile for clinical labs producing LDTs; products policies for LDT-producing labs require explicit MDR-extension consideration.

Permalink: /data#ldt-fda-rule

Illinois BIPA and Washington MHMDA expanded state-level biometric and health-data liability beyond HIPAA; cyber liability towers for diagnostic labs in Illinois and Washington should explicitly cover state-law claims alongside HIPAA breach response.

Permalink: /data#bipa-mhmda-cyber